<DOC>
	<DOCNO>NCT01594905</DOCNO>
	<brief_summary>Entecavir ( ETV ) plus Tenofovir Disoproxil Fumarate ( TDF ) combination show effective antiviral activity prevent development antiviral resistance hepatitis B e antigen ( HBeAg ) -positive -negative Chronic Hepatitis B ( CHB ) patient experienced multidrug resistance All subject orally take investigational drug daily 48 week . All subject assess baseline , Week 4 , 12 , 24 , 36 48 . Evaluations visit include vital sign , physical examination , laboratory test HBV DNA level . They also question adverse event concomitant medication . At baseline every six month thereafter , serum assay HBV serology . Genotypic analysis perform baseline 48 week .</brief_summary>
	<brief_title>Entecavir Plus Tenofovir Combination Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description>1 . It one unsolved issue unmet need CHB management develop optimal combination regimen manage multidrug resistant HBV characterize selection variant two class A signature genotypic resistant mutations1-3 2 . Currently add Adefovir ( ADV ) generally recommend Lamivudine ( LAM ) - Telbivudine ( LdT ) -resistant patient little known optimal management CHB patient develop multidrug resistance4 3 . Recent report show combination LAM plus ADV suppress HBV DNA effectively CHB patient resistance mutation drug . Only 12.2 % pt achieve virologic response ( VR ; HBV DNA &lt; 60 IU/mL ) 12 month multivariable analysis show LAM+ADV group presence rtA181V/T mutation independently associate decreased rate virologic response ( HBV DNA &lt; 2,000 IU/ml ) 12 months4 4 . ETV demonstrate effective patient ADV resistance patient prove YMDD mutation . In contrast , TDF show effective patient YMDD mutation necessarily patient ADV resistance.1-3 5 . Thus theoretically , combination potent nucleoside analogue nucleotide analogue non-overlapping resistance profile , ETV plus TDF , expect promising salvage treatment multidrug resistant HBV clinical evidence limit 6 . Therefore , study explore adequate management multidrug resistant patient use ETV plus TDF combination may lead fast great viral suppression prevent emergence antiviral resistance All subject orally take investigational drug daily 48 week . All subject assess baseline , Week 4 , 12 , 24 , 36 48 . Evaluations visit include vital sign , physical examination , laboratory test HBV DNA level . They also question adverse event concomitant medication . At baseline every six month thereafter , serum assay HBV serology . Genotypic analysis perform baseline 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . ≥ 20 year age 2 . History HBsAg positive 6 month 3 . Subject history genotypic resistance NAs two different class A 4 . Detectable HBV DNA ( ≥ 60 IU/mL ) rescue treatment regimen least 24 week 5 . HBeAgpositive negative 6 . Compensated liver disease ( ChildPugh A ) 7 . Signed write informed consent instruct objective procedure clinical study 1 . Subjects Alanine Aminotransferase ( ALT ) &gt; 10xUpper Limit normal ( ULN ) 2 . Coinfected hepatitis C virus ( HCV ) HIV 3 . Pregnant lactate woman 4 . Subject need longterm administration drug include immunosuppressive agent , agent related high risk hepatic/renal toxicity , agent influence renal excretion 5 . History liver transplantation plan liver transplantation 6 . Subject diagnose malignant tumor receive chemotherapy 7 . Subject hepatocellular carcinoma ( HCC ) history show potential HCC find suspicious region radiologic exam ( abdominal US CT ) serum Alpha Feto Protein ( AFP ) elevation 8 . Renal Insufficiency ( CLcr &lt; 50ml/min base CockcroftGault equation consider weight , age serum creatinine ) 9 . Patient liver disease chronic hepatitis B ( e.g . hemochromatosis , Wilson 's disease , alcoholic liver disease , nonalcoholic fatty liver disease , alpha 1antitrypsin deficiency etc . ) 10 . Subject history hypersensitivity study drug ingredient 11 . Subject involved clinical trial within 60 day prior study entry 12 . Subject investigator deems inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>To explore</keyword>
	<keyword>adequate management</keyword>
	<keyword>CHB</keyword>
	<keyword>Multidrug resistance</keyword>
</DOC>